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Medicare Beneficiaries More Likely To Receive Appropriate Ambulatory Services In HMOs Than In Traditional Medicare
ABSTRACT With quality-of-care bonus payments now available for Medicare Advantage health maintenance organizations (HMOs) and for accountable care organizations in traditional Medicare, the need to understand the relative quality of care delivered to Medicare enrollees has increased. We compared the quality of ambulatory care from 2003 through 2009 between beneficiaries enrolled in Medicare Advantage HMOs and those enrolled in traditional Medicare, and we assessed how the performance of various types of Medicare HMOs differed from that of traditional Medicare for these same measures. We found that beneficiaries in Medicare HMOs were consistently more likely than those in traditional Medicare to receive appropriate breast cancer screening, diabetes care, and cholesterol testing for cardiovascular disease. We also found that Medicare HMO physicians were rated less favorably by their patients than were physicians in traditional Medicare in 2003; however, by 2009 the opposite was true. Not-for-profit, larger, and older Medicare HMOs performed consistently more favorably on clinical measures and ratings of care than for-profit, smaller, and newer HMOs. Our results suggest that the positive effects of more-integrated delivery systems on the quality of ambulatory care in Medicare HMOs may outweigh the potential incentives to restrict care under capitated payments. As enrollment in Medicare Advantage grows, policy makers, health care providers, and beneficiaries have a correspondingly greater need to understand how the quality and costs of care in Medicare Advantage health plans compare to traditional fee-for-service Medicare. Whereas traditional Medicare has lacked explicit systems to improve the quality of care or limit costs, a major objective of Medicare HMOs has been to improve the integration and coordination of care in ways that could also improve the quality of care. However, because HMOs receive capitated payments from Medicare, they have incentives to limit the volume of care, which could undermine In two other studies of survey measures, Medicare Advantage enrollees were more likely to report having received pneumococcal and influenza vaccinations, but traditional Medicare enrollees rated their care more favorably than those in Medicare Advantage. 4, 5 We compared the quality of ambulatory care nationally during 2003-09 in Medicare HMOs and traditional Medicare, adjusting for sociodemographic factors and controlling for geographic region. We also assessed whether the quality of ambulatory care varied by health plan characteristics relative to traditional Medicare in the same local areas. We thus provide new evidence to guide policy makers overseeing Medicare.
Study Data And Methods
Study Design And Data Sources
We conducted an observational cohort study comparing quality of care between beneficiaries enrolled in Medicare HMOs matched to those in traditional Medicare in the same local areas during 2003-09. Since 1997 the Centers for Medicare and Medicaid Services (CMS) has required Medicare HMOs to report Healthcare Effectiveness Data and Information Set (HEDIS) quality measures for eligible enrollees each year. 6 Health plans, defined by a CMS contract in a single state or up to three adjacent states, collect these data from administrative billing or encounter data sets or using a hybrid approach in which medical records are also reviewed for services that might not be recorded in administrative data. 7 CMS has audited clinical quality measures reported by Medicare HMOs and found them to be highly accurate and consistent with technical specifications provided by the National Committee for Quality Assurance. 8 which are strongly correlated with quality of care in Medicare Advantage plans in the same local areas, 10 we matched almost all HMO enrollees to traditional Medicare beneficiaries with equivalent demographic characteristics in the same ZIP codes or counties.
Another strength of our study was its comparison of quality performance measures for individual HMOs relative to the traditional Medicare program within local areas, using hierarchical models to adjust for organizational characteristics and random effects of individual HMOs.
Study Cohort For the analysis of clinical performance measures, we excluded beneficiaries in each year whom we could not link to the Medicare Beneficiary Summary File; those in preferred provider organizations, which were relatively uncommon prior to 2006; those in private fee-for-service plans that were not required by CMS to report measures before 2010; and beneficiaries under age sixty-five and those enrolled less than twelve months (see online Appendix Exhibit A1). 11 We also excluded HMOs with fewer than 100 enrollees per measure or implausible data (from 0 to 5.7 percent of observations by measure), defined as plan-year estimates that were less than one-third of the grand mean across all HMOs for that year or two standard deviations above or below an individual HMO's average across all years (see the Appendix). After these exclusions, we matched HMO enrollees to traditional Medicare beneficiaries, using statistical weighting by age, sex, and race or ethnicity among beneficiaries who resided in the same five-digit ZIP code (78-90 percent of HMO enrollees per measure per year), county (9-20 percent), or state (0-2 percent) (see the Appendix).
11 In 2009 the final study cohort for clinical quality measures included 508,676 HMO enrollees eligible for breast cancer screening, 106,529 HMO enrollees with cardiovascular disease, and 127,771 HMO enrollees with diabetes, matched to comparable numbers of beneficiaries in traditional Medicare.
For survey measures, we excluded HMOs with fewer than 500 enrollees and otherwise applied eligibility criteria similar to those described above.We restricted this analysis to counties with survey respondents from both HMOs and traditional Medicare (Appendix Exhibit A2).
11 In 2009 the final study cohort for these measures included 128,706 HMO enrollees and 103,254 beneficiaries in traditional Medicare.
Study Variables The National Committee for Quality Assurance provided detailed specifications for clinical performance measures in each study year for five evidence-based clinical performance measures that could be readily created from Medicare claims for traditional Medicare. 9 These included screening mammography in the current or prior year for women ages 65-69; low-density lipoprotein (LDL) cholesterol testing in the current year for enrollees ages 65-75 with cardiovascular disease; and three monitoring services for enrollees ages 65-75 with diabetes, including hemoglobin A1c (HbA1c) testing and low-density lipoprotein cholesterol testing in the current year and a diabetic retinal exam in the current or prior year. We assessed performance on survey measures in HMOs and traditional Medicare by comparing county-level adjusted means for each measure in each year that controlled for enrollees' age, sex, race or ethnicity, and health status.We weighted these means by total HMO enrollment in each county to create national estimates (see the Appendix).
11 To categorize survey measures similarly to the dichotomous clinical quality measures, we assessed the proportion of respondents who rated their personal doctors and specialists at 9 or 10 on a 0-10 scale. As described above, we used hierarchical regression models to assess the survey performance measures for individual HMOs and by HMO characteristics in 2009.
Analyses were conducted using the statistical software SAS, version 9.2. We present the first and last year of data available for each measure between 2003 and 2009; findings for the intervening years (data not shown) showed consistent trends between the years presented. Twotailed p values are reported for statistical tests.
Limitations Our study had at least five potential limitations. First, although the number of clinical performance measures has risen considerably since 1997, we could create comparable variables from traditional Medicare claims for only five measures, all concerning processes rather than outcomes of care. Many other measures require data on medications or test results that were not available for traditional Medicare enrollees.
Second, most HMOs use a combination of administrative data and medical records to ascertain clinical quality measures, whereas the mea-sures we created for traditional Medicare were based only on Medicare claims. A prior study reported that 94 percent of elderly women who had a mammogram were accurately identified by Medicare claims. 12 Thus, if mammograms were similarly underreported for traditional Medicare in our national study, the 13.5-percentage-point lower rate of mammography in 2009 would be narrowed to 9.5 percentage points, but this difference would remain clinically important. Another prior study of diabetes measures in three Medicare health plans found that HbA1c and cholesterol testing-but not retinal exams for people with diabetes-were substantially underreported for elderly patients using administrative data alone, 13 because capitation or other payment arrangements that do not require claims submissions for payment may contribute to underreporting of lab tests in Medicare HMOs' administrative records. This finding suggests that information from medical records in HMOs raised the accuracy of their clinical measures based on the completion of lab tests closer to the more complete recording of billed lab services in traditional Medicare claims. With the advent of financial incentives for Medicare Advantage health plan performance on these measures, 14 the accuracy of HMO administrative data may improve.
Third, we could not adjust clinical quality measures for health status, as we did for survey measures of vaccinations and ratings of care. Nonetheless, reporting standards for clinical quality measures do not call for case-mix adjustment, and these measures apply to well-defined subgroups of patients for whom the service is almost always clinically indicated. Thus, unmeasured selection effects related to health status should have little effect on the provision of these services, but selection effects related to beneficiaries' preferences for preventive care may still contribute to the differences we observed.
Fourth, if better-performing HMOs have spillover effects on the quality of care for traditional Medicare beneficiaries in local areas, 15, 16 we may have underestimated the impact of Medicare HMOs on the overall quality of care. Finally, we were unable to assess whether increased payments to Medicare HMOs since the Medicare Modernization Act contributed to their better performance on clinical quality measures relative to traditional Medicare.
Study Results
The number of HMOs more than doubled from 120 in 2003 to 280 in 2009, with a corresponding increase in total enrollment from approximately 3.1 million to 5.6 million members (Appendix Exhibit A3).
11 Over this period, the proportion of enrollees in for-profit HMOs rose from 57.5 percent to 62. 4 In 2009 enrollees in HMOs that were not-forprofit, larger, and more established reported better ratings of personal physicians and slightly worse ratings of specialists relative to local enrollees in traditional Medicare (Exhibit 3). Enrollees in HMOs that were for-profit, smaller, and newer rated both of the vaccinations and their specialists less favorably than their counterparts in traditional Medicare. Our study also demonstrated substantial differences in performance among different types of HMOs relative to traditional Medicare. As in prior studies, [18] [19] [20] not-for-profit HMOs performed better than for-profit HMOs. Larger, more established HMOs also performed consistently better relative to traditional Medicare than smaller or newer HMOs, which suggests that the former group has more effective systems to promote quality of care or to contract selectively with higher-quality providers. 21 Betterperforming HMOs may also reduce or eliminate enrollee cost sharing for specific services, such as screening mammography. 22 
Conclusion
The policy importance of performance measures of quality of care has increased with passage of the Affordable Care Act, which authorized CMS to begin providing financial bonuses to Medicare Advantage health plans in 2012. These bonuses are based on a "star" rating system for health plans that demonstrate superior performance on clinical quality and survey measures. 14 Furthermore, the Affordable Care Act authorized CMS to begin contracting with accountable care organizations that will share financial risk with CMS for the costs and quality of care received by the traditional Medicare beneficiaries they serve. 23 Through the Medicare Pioneer Accountable Care Organizations and Shared Savings Programs, these organizations are eligible to receive bonus payments, initially related to reporting quality measures and subsequently to achieving higher quality of care. 24 The performance measures include survey measures similar to those analyzed in this study and several clinical quality measures, such as screening mammography and HbA1c testing, that can be derived from Medicare claims. 9 These recent parallel expansions of financial incentives for achieving better quality of care in Medicare Advantage and traditional Medicare heighten the need for performance measures that can be compared between these two major components of the Medicare program. Such measures will enable policy makers, health care providers, and Medicare beneficiaries to assess whether the quality of care in Medicare Advantage health plans differs from that provided within accountable care organizations and from that provided outside these organizations in the 
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